Movement Alert｜DotBio-B Rises 7.07% in Regular Trading, DB-1310 Clinical Data Unveiled at ASCO and Partner Avenzo Completes Nasdaq Listing

Market Focus07-20

On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.

On the news front, the company recently presented initial Phase I/IIa results for DB-1310 in advanced solid tumor patients via an oral presentation at the ASCO annual meeting. DB-1310 had previously established a collaboration with AstraZeneca to explore combination therapy with osimertinib. Concurrently, partner Avenzo announced on July 16 its Nasdaq listing through a reverse merger, completing a US$215 million oversubscribed PIPE financing. A core asset of Avenzo is the EGFR/HER3 bispecific ADC DB-1418 licensed from DotBio, further validating the commercial value of the company's pipeline.

Within the Biotechnology sector, the overall sector showed broad strength. Among individual stocks, Remegen up 7.28%, Akeso up 5.83%, 3SBio up 4.77%, Innovent Bio up 3.88%, BeiGene up 3.39%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139325586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139325586","market":"us","top_or_hot":-1,"title":"Movement Alert｜DotBio-B Rises 7.07% in Regular Trading, DB-1310 Clinical Data Unveiled at ASCO and Partner Avenzo Completes Nasdaq Listing","media":"Market Focus","content":"<p><p>On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.</p><p>On the news front, the company recently presented initial Phase I/IIa results for DB-1310 in advanced solid tumor patients via an oral presentation at the ASCO annual meeting. DB-1310 had previously established a collaboration with AstraZeneca to explore combination therapy with osimertinib. Concurrently, partner Avenzo announced on July 16 its Nasdaq listing through a reverse merger, completing a US$215 million oversubscribed PIPE financing. A core asset of Avenzo is the EGFR/HER3 bispecific ADC DB-1418 licensed from DotBio, further validating the commercial value of the company's pipeline.</p><p>Within the Biotechnology sector, the overall sector showed broad strength. Among individual stocks, Remegen up 7.28%, Akeso up 5.83%, 3SBio up 4.77%, Innovent Bio up 3.88%, BeiGene up 3.39%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio-B Rises 7.07% in Regular Trading, DB-1310 Clinical Data Unveiled at ASCO and Partner Avenzo Completes Nasdaq Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio-B Rises 7.07% in Regular Trading, DB-1310 Clinical Data Unveiled at ASCO and Partner Avenzo Completes Nasdaq Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.</p><p>On the news front, the company recently presented initial Phase I/IIa results for DB-1310 in advanced solid tumor patients via an oral presentation at the ASCO annual meeting. DB-1310 had previously established a collaboration with AstraZeneca to explore combination therapy with osimertinib. Concurrently, partner Avenzo announced on July 16 its Nasdaq listing through a reverse merger, completing a US$215 million oversubscribed PIPE financing. A core asset of Avenzo is the EGFR/HER3 bispecific ADC DB-1418 licensed from DotBio, further validating the commercial value of the company's pipeline.</p><p>Within the Biotechnology sector, the overall sector showed broad strength. Among individual stocks, Remegen up 7.28%, Akeso up 5.83%, 3SBio up 4.77%, Innovent Bio up 3.88%, BeiGene up 3.39%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1139325586","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139325586","pubTimestamp":1784514760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.On the news front, the company recently presented initial Phase I/IIa results for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DotBio-B常规交易上涨7.07%，DB-1310临床数据亮相ASCO，合作伙伴Avenzo完成纳斯达克上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.On the news front, the company recently presented initial Phase I/IIa results for DB-1310 in advanced solid tumor patients via an oral presentation at the ASCO annual meeting. DB-1310 had previously established a collaboration with AstraZeneca to explore combination therapy with osimertinib. Concurrently, partner Avenzo announced on July 16 its Nasdaq listing through a reverse merger, completing a US$215 million oversubscribed PIPE financing. A core asset of Avenzo is the EGFR/HER3 bispecific ADC DB-1418 licensed from DotBio, further validating the commercial value of the company's pipeline.Within the Biotechnology sector, the overall sector showed broad strength. Among individual stocks, Remegen up 7.28%, Akeso up 5.83%, 3SBio up 4.77%, Innovent Bio up 3.88%, BeiGene up 3.39%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139325586","isCrawlerRequest":true}